Akanksha Mahajan
Bhawna Gupta
Adam Peterson3,4- 1Monash Health, Melbourne, VIC, Australia
- 2Department of Public Health, Torrens University, Melbourne, VIC, Australia
- 3Gastroenterology Department, Monash Health, Melbourne, VIC, Australia
- 4School of Clinical Sciences at Monash Health, Monash University, Melbourne, VIC, Australia
- 5Department of Gastroenterology, Royal Melbourne Hospital, Parkville, VIC, Australia
- 6Department of Gastroenterology, Western Health, Footscray, VIC, Australia
Introduction: Inflammatory bowel disease includes a range of chronic gastrointestinal disorders, most commonly Crohn’s Disease (CD) and ulcerative colitis (UC). This systematic review and meta-analysis aims to evaluate the effect of passive smoking on incidence and disease outcomes of CD and UC.
Methods: This review was conducted according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines. Meta-analysis was performed according to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines. The literature was systematically searched from inception until May 2025 to identify relevant studies from a range of databases including MEDLINE, CINAHL, Embase, Scopus and Cochrane Library.
Results: The initial search yielded 151 articles, with 32 studies deemed relevant for inclusion. Significant associations with passive smoking exposure were seen in 8 out of 20 studies for increased risk of CD and 3 out of 17 studies for UC. Meta-analysis found that passive smoking during childhood (OR 1.19, 95% CI 1.05–1.35) and exposure to smoking during pregnancy (OR 1.27, 95% CI 1.03–1.55) was associated with increase in odds of CD; however neither exposure was associated with an increased odds of UC. Associations with CD were also not confirmed in sensitivity analysis of higher-quality studies. Passive smoking was associated with disease complications including pouch-itis and backwash-ileitis in UC; while exposure to smoking during pregnancy was associated with hospitalisation and colorectal neoplasia in CD. There is inconclusive evidence surrounding the effects of passive smoking on need for medications and surgery.
Discussion: Findings of this review highlight the importance of educating on harms of passive smoking.
Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251035510.
Introduction
Inflammatory bowel disease (IBD) is comprised of a group of chronic relapsing–remitting inflammatory disorders of the gastrointestinal tract. IBD is broadly classified into Crohn’s disease (CD) and ulcerative colitis (UC) which differ in location, histology and clinical phenotype (1). IBD presents a growing global burden of disease, with increasing prevalence of cases, deaths and DALYs (disability adjusted life years). A total of 147 out of 204 countries or territories studied in the Global Burden of Disease database demonstrated an increase in the age-standardised prevalence rate of IBD from 1990 to 2019 (2). While IBD has conventionally been considered a disease of Western nations; over the past three decades, there has been a rising incidence in newly industrialised countries in Africa, Asia, and South America while prevalence remains high in Europe, North America and Oceania (3). Moreover, there is compounding prevalence of IBD in Western countries, because even though the incidence is stabilising, new diagnoses of IBD continue to increase the prevalent population of IBD patients (4). Due to natural population growth over time, there is forecasted to be doubling of prevalence from 0.5 to 1.0% from 2008 to 2030 in some regions of North America and Europe (5). This change in disease epidemiology in line with the westernisation of countries with historically low rates of IBD supports that environmental factors are involved in disease pathogenesis (6). This environmental influence is further supported by a Canadian study by Benchimol et al. (7) which found that offspring of immigrants from low-incidence regions have a similar risk of acquiring IBD as individuals in Western populations.
The pathogenesis of IBD is multifactorial with an interplay between genetic susceptibility and environmental factors which drives dysregulation in immune response, intestinal epithelial barrier dysfunction and an altered gut microbiome leading to an abnormal immune response to intestinal flora (6, 8–10). The interaction between multiple pathogenic factors in the environment, genome, microbiome and immunological factors leads to a network effect which triggers disease. This is referred to as the ‘IBD interactome’ (10). Although family history is the greatest risk factor for developing IBD, genetic susceptibility does not explain the variance in disease incidence (11, 12). Modifiable risk factors which have been implicated in the pathogenesis of IBD include smoking, poor sanitation, air and water pollution, diet, food additives and antibiotic use (13). There is growing evidence to suggest that the dynamic balance between gut flora, and host defensive responses in intestinal mucosal epithelium has a pivotal role in the initiation of IBD (6).
This intestinal inflammation is associated with heterogenous clinical presentations with abdominal pain, diarrhoea, and bloody stools; as well as extra intestinal manifestations and systemic symptoms such as weight loss and fatigue (14). IBD is associated with significant morbidity, with associated hospitalisations and surgeries leading to substantial healthcare costs and burden on healthcare systems (15–17). There are also extensive indirect costs through loss of productivity, with a Swedish cost-effectiveness modelling study finding that these accounted for around 50% of disease-associated costs (4).
Although active smoking is an established risk factor for CD (18), there remains controversy surrounding its influence on the development and course of UC. Studies have shown that smoking can downregulate apical tight junction protein genes, leading to increased epithelial paracellular permeability which triggers cellular apoptosis, mucosal erosion and ulcers that can contribute to intestinal epithelium damage (19, 20). Moreover, IBD has been associated with an imbalance in the composition of host-associated microbiota and a shift towards potentially pathogenic microorganisms; known as dysbiosis (21). Cigarette smoking can cause a shift in microbiome composition and activity in the colon; as evidenced in a Korean population-based study which found altered faecal microbiota composition in current smokers compared to those who had never smoked (20, 22). Similarly, a study on patients undergoing endoscopy for upper GI symptoms, iron deficiency or Crohn’s disease found that there was reduced bacterial diversity in the upper small intestinal mucosa of current smokers as compared to never smokers (23). Moreover, chronic cigarette smoking is associated with impaired gas exchange and consequently systemic and colonic tissue ischemia which drives intestinal epithelial barrier dysfunction (24).
The role of passive smoking in both CD and UC is underexplored. During cigarette combustion, accumulated chemicals are distributed among mainstream smoke that is inhaled into the lungs during the puffs, side stream smoke that is released by the burning tip of the cigarette, secondhand smoke that is a mixture of sidestream and exhaled mainstream smoke, and thirdhand smoke which is the toxic tobacco residue found on surfaces exposed to smoke, as well as the ashes and cigarette butts (25). Hence, both smokers and non-smokers in the presence of smokers are exposed to known toxic compounds in cigarette smoke, including nicotine, heavy metals, nitrosamines, phenyls and insecticides (25). Approximately 37% of the population globally is exposed to the smoke emitted from the burning end of tobacco products or exhaled from smokers; known as passive smoking; with higher rates of exposure among women and children compared to men (26, 27). In 2021, 2,709 million people were exposed to passive smoking, and the five countries with the largest populations exposed were China, India, Indonesia, Pakistan and United States (28). Children are particularly vulnerable to the harmful effects of passive smoking, as they are involuntarily exposed to this for years, if living with family members who smoke at home. The Global Burden of Disease Study 2019 estimates that 50,000 deaths and 4,500,000 disability-adjusted life-years among children under 14 years of age were attributable to passive smoking (29).
This systematic review aims to evaluate the effect of passive smoking in early life (prenatal and during childhood, i.e. <18 years of age) on incidence and disease outcomes of CD and UC. This is the first review to investigate the effect of passive smoking on disease outcomes in IBD.
Methods
This study is registered at the International Register of Prospective Systematic Reviews (PROSPERO) under CRD420251035510. This review was conducted according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines.
Eligibility criteria
All observational studies that evaluated effect of passive smoking exposure during gestation or childhood (age <18 years) on incidence of CD or UC were included. Passive smoking exposure during gestation refers to maternal active or passive smoking during pregnancy. Patients diagnosed with CD or UC at any age, and in any healthcare setting were considered. Patients diagnosed with Inflammatory Bowel Disease Unclassified or microscopic colitis were excluded from this review.
Search strategy
The literature was systematically searched from inception until May 2025 to identify relevant studies from a range of databases including MEDLINE, CINAHL, Embase, Scopus and Cochrane Library. An English translation was obtained for any articles not published in English. The following key words were used: ‘Passive smok*’, ‘second hand smok*’, ‘inflammatory bowel disease’, ‘Crohn disease’ and ‘ulcerative colitis’; combined with Boolean operators. This search was supplemented with a manual search of the reference lists of relevant articles as well as grey literature such as conference abstracts and posters.
Data extraction
Search data were uploaded to the Endnote software, and duplicates were removed. Two reviewers (AM and BG) independently screened the title and abstract of the identified citations. Full texts were subsequently independently screened by two reviewers (AM and BG) for eligibility. Disagreements were resolved by discussion among the authors with a consensus decision being reached. Data was extracted from eligible studies including year of publication, study design, sample size, definition of exposure and outcome, inclusion and exclusion criteria, adjusted covariates, measures of association including both unadjusted and adjusted odds ratios. Outcome data related to cases of CD, cases of UC, presence of dose response relationship, risk of complicated B2 (stricturing) or B3 (penetrating) disease as per the Montreal Classification of IBD (30), need for biologics, hospitalisation risk, number of cases requiring immunosuppression, number requiring steroid therapy, number requiring surgery; and incidence of colorectal neoplasia were collected. If separate measures of association were reported with regards to sources of passive smoking exposure (e.g., in the home, from mother, father, other etc.), then the most inclusive measure of association was used. Passive smoking exposure during childhood was defined as exposure to smoking within the household or elsewhere from any persons, below the age of 18 years. Passive smoking exposure during pregnancy was defined as maternal smoking during any stage of pregnancy.
Quality assessment
The quality of studies was assessed by two authors (AM and BG), with any disagreements resolved by consensus. Quality assessment was completed using the Newcastle-Ottawa Scale, which contains eight items, divided into three categories: selection, comparability, and depending on the study type, outcome (cohort studies) or exposure (case–control studies). The scoring ranges from one to nine stars, as a maximum of one star can be assigned per item with the exception of the item related to comparability which allows for two stars (31). Scoring is as follows:
• Good quality = 3–4 stars in selection AND 1–2 stars in comparability AND 2–3 stars in outcome.
• Fair quality = 2 stars in selection AND 1–2 stars in comparability AND 2–3 stars in outcome.
• Poor quality = 0–1 star in selection OR 0 star in comparability OR 0–1 star in outcome (31).
Statistical analysis
The meta-analysis was performed according to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines. Review Manager (RevMan) version 7.2.0 was used to conduct all statistical analyses. Forest plots were generated to demonstrate the effect of each study and the pooled effect size for studies with the same outcome. A probability value of p < 0.05 was considered statistically significant. A random effects model using the DerSimonian and Laird method was applied for meta-analysis as it incorporates heterogeneity of treatment effects between studies into the analysis (32). Unadjusted odds ratio (OR) along with their corresponding 95% CI were used as the effects of measure for dichotomous outcomes related to incidence and/or complications associated with inflammatory bowel disease. The authors of this review manually calculated the unadjusted OR when it was not included in a publication, but adequate data was provided for calculation.
For each overall effect size, heterogeneity was examined using Cochran’s Q statistic (measure of weighted square deviations), with N − 1 degrees of freedom (where N is the number of studies), between studies variance (T2), and ratio of the true heterogeneity to total observed variation (I2). Potential causes for heterogeneity were evaluated through sensitivity analysis. Publication bias was assessed through visual inspection of funnel plots.
Results
Search results and study characteristics
The PRISMA flow diagram in Figure 1 shows that the initial search yielded 151 articles. Following the removal of duplicates, the title and abstracts of 114 articles, and subsequently full texts of 42 articles, were reviewed by 2 authors (AM and BG), with 32 studies deemed relevant for inclusion. This review includes 25 studies which evaluated the effect of passive smoking on incidence of CD and UC, with 21 case control studies, 3 prospective cohort studies, and one Mendelian randomisation study. It includes 6 cohort studies which assessed the effect of passive smoking on complications of CD (33–38), and 4 studies on complications of UC, of which there were 3 cohort studies (36–38) and 1 cross sectional study (39). Included studies were of varying quality; with 11 high quality studies (33, 35, 38, 40–47), 5 of fair quality (48–52), and 16 poor quality studies (34, 36, 37, 39, 53–63); as detailed in Supplementary Table 1. Quality of the study by Yu et al. (64) was not evaluated using the Newcastle Ottawa Scale as this scale is not applicable to Mendelian randomisation studies.
Figure 1. PRISMA flowchart.
This systematic review includes studies across a range of geographic locations, with 11 studies from Europe (5 from United Kingdom, 2 from Sweden, 1 from Sweden and Norway, and 1 each from France, Finland and the Netherlands), 5 studies from Asia (3 from Japan, 1 each from Qatar and Israel), and 7 from North America (2 from Canada and 5 from the United States of America). However, there was only one study conducted in Africa and South America respectively, and none conducted in Oceania that were eligible for inclusion in this review. The studies included were all conducted in industrialised countries, except for 1 study in Brazil which is an emerging region. Hence, the review may not be representative of the entire global population of IBD patients. Although this may be partially attributable to the low incidence of IBD in South America and Africa, incidence of IBD in these regions is rising alongside increasing industrialisation, and there is a poor understanding of this evolving epidemiology which should be addressed with future research (18, 65). There is also a need for further research on this subject in Oceania, which has longstanding high incidence and prevalence rates of IBD (66).
Effects of passive smoking on incidence of IBD
A total of 25 studies, with 81,257 patients with CD and 5,349 patients with UC were included in the section of the review on incidence of IBD. Significant associations with passive smoking exposure were seen in 8 out of 20 studies for increased risk of CD and 3 out of 17 studies for UC. Interestingly, a Mendelian randomisation study by Yu et al. found a significant association between workplace exposure to passive smoking and incidence of UC, but not CD (64). Meanwhile, a case control study by Eliakim et al. (53) found no association between passive smoking at work and either CD or UC. A dose response relationship was reported in 2 studies for passive smoking exposure during childhood on incidence of CD (50, 63) and 1 for UC (51). Similarly, another study found that greater number of years of living with a smoker was associated with slightly increased odds of developing CD (44). Studies also reported that higher number of cigarettes smoked during pregnancy (52) or in the household during childhood (56) increased risk of IBD; although associations with CD and UC were not reported separately.
Meta-analysis found that passive smoking during childhood (OR 1.19, 95% CI 1.05–1.35) and exposure to passive smoking in utero via maternal active or passive smoking, (OR 1.27, 95% CI 1.03–1.55) was associated with increase in odds of CD; however, neither exposure was associated with incidence of UC; as demonstrated in the forest plots in Figures 2–5. Sensitivity analysis which only included studies of high quality, found that there was no significant association between passive smoking during pregnancy or life and incidence of either CD or UC.
Figure 2. Passive smoking exposure and risk of CD.
Figure 3. Passive smoking exposure and risk of UC.
Figure 4. Maternal smoking during pregnancy and odds of CD in offspring.
Figure 5. Maternal smoking during pregnancy and odds of UC in offspring.
Funnel plots for studies evaluating association between childhood passive smoking exposure as well as during pregnancy for both CD and UC had a symmetrical distribution, suggesting that publication bias was not present, as shown in Supplementary Figures 1–4.
Effects of passive smoking on complications of IBD
A total of 7 studies, with 2,962 patients with CD and 1,238 patients with UC were included in the review of effect of passive smoking on disease outcomes of IBD. Meta-analysis was not performed due to a limited number of studies reporting on each outcome of interest, as well as heterogeneity across the included studies. Two studies found that passive smoking exposure was not significantly associated with disease outcomes of CD (33, 34), but passive smokers with UC were significantly more likely to develop pouchitis (inflammation of the surgically created ileal pouch) after undergoing ileoanal pouch anastomoses surgery, and backwash ileitis (36). Four studies evaluated risk of hospitalisations associated with passive smoking in patients with CD (33, 34, 36, 37), while 3 studies evaluated this for UC (36, 37, 39). Although one study found that exposure to maternal smoking during pregnancy was significantly associated with hospitalisation in CD (33), no significant association was found between passive smoking during life and hospitalisation for CD or UC in any of the included studies.
However, there is inconclusive evidence surrounding the effects of passive smoking on need for medications and surgery. While one study found a positive association between requirement for immunosuppression with anti-tumour necrosis factor-α monoclonal antibody infliximab and passive smoking exposure for CD (36); others did not find any significant association for immunosuppression (34) or steroid use (34, 36) in CD or UC (36). Contrasting outcomes were also observed with respect to risk of surgery. One study found it was associated with increased likelihood of intestinal surgery in CD (35), whilst another found no association with either CD and UC (36). Interestingly, passive smoke exposure was associated with increased risk of colorectal neoplasia in CD but not UC (38).
Discussion
This systematic review and meta-analysis found that exposure to passive smoking during pregnancy and childhood is associated with an increased incidence of CD but not UC. This observation is supported by a positive dose response relationship between increasing number of cigarettes smoked and risk of IBD. However, the association was not identified following a sensitivity analysis for only high quality studies, and reflects the conclusion of Jones et al. who reported no association between childhood passive smoke exposure and CD or UC (67).
It is possible that the association was not seen in the sensitivity analysis due to reduced statistical power from a smaller sample size. Importantly, an increased risk of IBD was observed in persons exposed to passive smoking, in the study by Basson et al. (43), which was the largest of the high quality studies (Figures 6–9).
![Forest plot showing a meta-analysis of passive smoking exposure and its effects, categorized into case control and cohort studies. Each study's odds ratio is displayed with a confidence interval. Subtotals for sections and an overall odds ratio of 1.17 [0.93, 1.48] are provided. Weight percentages and heterogeneity statistics are included.](https://www.frontiersin.org/files/Articles/1670320/fpubh-13-1670320-HTML/image_m/fpubh-13-1670320-g006.jpg)
Figure 6. Sensitivity analysis including only high quality studies for passive smoking during childhood and CD.
Figure 7. Sensitivity analysis including only high quality studies for passive smoking during childhood and UC.
Figure 8. Sensitivity analysis including only high quality studies for maternal smoking during pregnancy and CD.
Figure 9. Sensitivity analysis including only high quality studies for maternal smoking during pregnancy and UC.
Mechanistic animal studies support the biological plausibility of the impact of passive smoke exposure on risk of IBD. Tobacco smoke has been shown to alter mucous composition in murine models (68), alter the human microbiota (69), and impair intestinal epithelial barrier function in murine small bowel (70). Although interestingly, the colon was not affected. Similarly, smoking increases inflammatory cell recruitment and pro-inflammatory cytokine release (71). However, tolerogenic effects have been observed in UC as compared to CD and may explain differences in epidemiological outcomes for these patients. Passive smoke exposure has been specifically examined in a rat model of trinitrobenzene sulfonic acid-induced experimental colitis, where exposure to 2% or 4% cigarette smoke-filled air resulted in increased colonic oedema, mucosal lesion area, and histopathological score. Mucosal myeloperoxidase activity and tumour necrosis factor α level as markers of colitis activity were also elevated (72). Passive smoking exposure has also been shown to significantly increase the expression of intestinal α7 nicotinic acetylcholine receptors (α7nAChRs) which play a key role in the cholinergic anti-inflammatory pathway (72). α7nAChR is upregulated in UC and CD intestinal tissue (73), however some preclinical studies have shown that it may have a protective role and its significance remains unclear (74–76).
The effect of smoking and indeed passive smoke exposure on UC is less clear than in CD, and our review found no significant association with incidence of UC. There was no association between passive smoking and UC complications except for pouchitis and backwash- ileitis, which are inherently disorders of the small bowel rather than colon. Although this is the first review to study the effects of passive smoking on IBD complications; our findings are corroborated by previous meta-analyses which found that active smoking was not associated with surgery or flare of disease activity in UC (77, 78). One previous review has explored the effects on incidence of IBD (67), however this paper includes a much larger number of studies and consequently greater sample population, leading to increased reliability and representativeness of conclusions.
There are a number of reasons why passive smoking may more likely contribute to development of CD but not UC. Cigarette smoke has been associated with increased apoptosis in follicle-associated epithelium overlying Peyer’s patches in mouse models as well as an upregulation in mRNA expression of CCL9 and CCL20, two important chemokines in CD pathogenesis (79). This epithelial barrier damage may lead to exposure of lumen antigens, which can be recognized by immune cells whose recruitment is increased, inducing the development of CD (80).
Moreover, a murine study demonstrated that cigarette smoke exposure damages the ileal mucosal barrier, generating greater permeability to bacteria—this modification to gut microbiota is likely to more significantly influence development of CD whereas development of UC has greater association with changes in humoral immunity (80). Additionally, the immunomodulatory and anti-inflammatory effects of nicotine and carbon monoxide may predominate in UC but not in ileal CD, due to the different expression of receptors and other molecules by immune cells residing in the different parts of the intestine that are affected in CD or UC (80). The immunomodulatory effect of nicotine is mediated by the activation of α7-nAChR in immune cells which, although having controversial and multifactorial mechanisms of actions, has been found to decrease production of pro-inflammatory cytokines, and contribute to immunosuppressive function of CD4+ CD25+ regulatory T cells, reducing NF-κB activation and IL-2 production (81). Carbon monoxide, the main component of the gas phase of cigarette smoke, has also been associated with reduced production of pro-inflammatory cytokines.
Smoking is an independent risk factor for colorectal neoplasia (CRN) (82), however only a single study by Van der Sloot et al. (38) assessed this risk in IBD. Whilst there was an association with previous smoking and CRN, there was no significant association found between passive smoking and CRN in patients with UC (38). This finding may be attributable to recall bias given that this was a retrospective cohort study or may suggest a dose response whereby passive smoking has not provided sufficient exposure to the toxins and carcinogens present in cigarettes as compared to active smoking. Further studies are required to corroborate the results of this single study.
Our review found some evidence to support a dose response relationship between passive smoking exposure during childhood and pregnancy and incidence of UC and CD (44, 45, 50–52, 56, 63). However, given the small sample size and uneven distribution across different degrees of smoking exposure during childhood/pregnancy in the existing literature, there is a need for further research to more rigorously examine this.
This review highlights the importance of health policies and public health interventions targeted at cessation of smoking, particularly at home. Several interventions have been implemented in recent years to address this. There is evidence to support that smoke-free regulations such as the smoke-free outdoor regulation across the WHO European Region are effective in reducing second hand smoking exposure when extensive or complete smoking bans were implemented (83, 84). However, partial bans are less effective in reducing second hand smoke exposure (84). Hence, there is a role for stricter legislation regarding smoking in public places. Follow-up data from monitoring and evaluation of the efficacy of and compliance to these interventions for second hand smoking reduction is essential to guide future laws and policy. For instance, the Tobacco Control Scale (85) has been used to research the effectiveness of tobacco control policy in the European Union annually. However, these programs to reduce smoking in public places will not address exposure in the home and further education may be required in order to address the association between passive smoking during pregnancy and childhood and incidence of IBD identified in this review. Smoking is also more prevalent in lower socioeconomic groups which already have higher morbidity from chronic disease; hence interventions targeting smoking cessation and education regarding the risks of second hand smoke for these vulnerable populations may be effective in preventing the exacerbation of existing health inequities (86, 87).
Early smoking cessation education and intervention for patients and more importantly families, to address risk factors such as passive smoking is crucial to reduce economic strain of IBD management. For instance, a study conducted in Australia on resource use for management of IBD found that inpatient IBD management and treating active disease was associated with significantly higher costs compared to management of outpatients and disease in remission, respectively (15, 17). Proactive care may help prevent disease from reaching a severity where reactive and resource-intensive management is required such as hospital admission and treatment with biologics (15, 16).
Limitations
All of the included studies measured passive smoking exposure through self-reported data from IBD patients, except for the cohort study by Nowak et al. in which presence and concentration of cotinine in urine was used an objective marker of smoking exposure. Thus, the data is subjected to reporting bias as well as recall bias; especially given that most included studies were retrospective. There is a particular risk for social desirability bias and consequent falsely low exposure reporting given the social unacceptability and stigma surrounding smoking during pregnancy and around children, which may have led to parents not disclosing this exposure to IBD patients, or hesitation in accurate reporting by patients themselves for fear of judgement. Moreover, many of the included case–control studies did not specify how CD or UC was diagnosed in cases, or measures to determine that controls definitely did not have IBD (i.e., symptom free or previous colonoscopy); which further reduces reliability of findings. Disease complications and their definitions were also not standardised across included studies, and this did not allow for meta-analyses to be performed for these outcomes.
Additionally, only one of the included studies reported duration of maternal smoking during pregnancy or specific number of years of passive smoking exposure during childhood; which limits the ability to draw conclusions regarding potentially varying impacts of passive smoking exposure at different points in gestation or evaluation of a dose response relationship with respect to duration of exposure.
Conclusion
This review suggests a possible link between childhood passive smoking and Crohn’s disease, but this was not confirmed in sensitivity analysis of higher-quality studies. No consistent associations were found for ulcerative colitis or disease outcomes. These results should be interpreted cautiously, and further high-quality prospective studies examining the effect of passive smoking on disease outcomes are required for both CD and UC.
Data availability statement
The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding authors.
Author contributions
AM: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Software, Writing – original draft, Writing – review & editing. BG: Conceptualization, Data curation, Investigation, Methodology, Resources, Supervision, Writing – review & editing. AP: Supervision, Writing – review & editing. GI: Writing – review & editing. ZV: Writing – review & editing.
Funding
The author(s) declare that no financial support was received for the research and/or publication of this article.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The authors declare that no Gen AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh.2025.1670320/full#supplementary-material
References
1. Verstockt, B, Bressler, B, Martinez-Lozano, H, McGovern, D, and Silverberg, MS. Time to revisit disease classification in inflammatory bowel disease: is the current classification of inflammatory bowel disease good enough for optimal clinical management? Gastroenterology. (2022) 162:1370–82. doi: 10.1053/j.gastro.2021.12.246
2. Wang, R, Li, Z, Liu, S, and Zhang, D. Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the global burden of disease study 2019. BMJ Open. (2023) 13:e065186. doi: 10.1136/bmjopen-2022-065186
3. Ng, SC, Shi, HY, Hamidi, N, Underwood, FE, Tang, W, Benchimol, EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. (2017) 390:2769–78. doi: 10.1016/S0140-6736(17)32448-0
4. Hansson-Hedblom, A, Almond, C, Borgström, F, Sly, I, Enkusson, D, Troelsgaard Buchholt, A, et al. Cost-effectiveness of ustekinumab in moderate to severe Crohn's disease in Sweden. Cost Eff Resour Alloc. (2018) 16:28. doi: 10.1186/s12962-018-0114-y
5. Kaplan, GG, and Windsor, JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. (2021) 18:56–66. doi: 10.1038/s41575-020-00360-x
6. Xavier, RJ, and Podolsky, DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. (2007) 448:427–34. doi: 10.1038/nature06005
7. Benchimol, EI, Mack, DR, Guttmann, A, Nguyen, GC, To, T, Mojaverian, N, et al. Inflammatory bowel disease in immigrants to Canada and their children: a population-based cohort study. Am J Gastroenterol. (2015) 110:553–63. doi: 10.1038/ajg.2015.52
8. Xia, H-s, Liu, Y, Fu, Y, Li, M, and Wu, Y-q. Biology of interleukin-38 and its role in chronic inflammatory diseases. Int Immunopharmacol. (2021) 95:107528. doi: 10.1016/j.intimp.2021.107528
9. Hajj Hussein, I, Dosh, L, Al Qassab, M, Jurjus, R, El Masri, J, Abi Nader, C, et al. Highlights on two decades with microbiota and inflammatory bowel disease from etiology to therapy. Transpl Immunol. (2023) 78:101835. doi: 10.1016/j.trim.2023.101835
10. de Souza, HSP, Fiocchi, C, and Iliopoulos, D. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol. (2017) 14:739–49. doi: 10.1038/nrgastro.2017.110
11. Hugot, J-P, Chamaillard, M, Zouali, H, Lesage, S, Cézard, J-P, Belaiche, J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. (2001) 411:599–603. doi: 10.1038/35079107
13. Abegunde, AT, Muhammad, BH, Bhatti, O, and Ali, T. Environmental risk factors for inflammatory bowel diseases: evidence based literature review. World J Gastroenterol. (2016) 22:6296–317. doi: 10.3748/wjg.v22.i27.6296
14. Fakhoury, M, Negrulj, R, Mooranian, A, and Al-Salami, H. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res. (2014) 7:113–20. doi: 10.2147/JIR.S65979
15. Jackson, B, Con, D, Ma, R, Gorelik, A, Liew, D, and De Cruz, P. Health care costs associated with Australian tertiary inflammatory bowel disease care. Scand J Gastroenterol. (2017) 52:851–6. doi: 10.1080/00365521.2017.1323117
16. Lee, J, Im, JP, Han, K, Kim, J, Lee, HJ, Chun, J, et al. Changes in direct healthcare costs before and after the diagnosis of inflammatory bowel disease: a nationwide population-based study. Gut Liver. (2020) 14:89–99. doi: 10.5009/gnl19023
17. Ui-Haq, Z, Causin, L, Kamalati, T, Kahol, D, Vaikunthanathan, T, Wong, C, et al. Health-care resource use and costs associated with inflammatory bowel disease in Northwest London: a retrospective linked database study. BMC Gastroenterol. (2024) 24:480. doi: 10.1186/s12876-024-03559-3
18. Caron, B, Honap, S, and Peyrin-Biroulet, L. Epidemiology of inflammatory bowel disease across the ages in the era of advanced therapies. J Crohns Colitis. (2024) 18:ii3–ii15.
19. Capaldo, CT, Powell, DN, and Kalman, D. Layered defense: how mucus and tight junctions seal the intestinal barrier. J Mol Med (Berl). (2017) 95:927–34. doi: 10.1007/s00109-017-1557-x
20. Papoutsopoulou, S, Satsangi, J, Campbell, BJ, and Probert, CS. Review article: impact of cigarette smoking on intestinal inflammation—direct and indirect mechanisms. Aliment Pharmacol Ther. (2020) 51:1268–85. doi: 10.1111/apt.15774
21. Ni, J, Wu, GD, Albenberg, L, and Tomov, VT. Gut microbiota and IBD: causation or correlation? Nat Rev Gastroenterol Hepatol. (2017) 14:573–84. doi: 10.1038/nrgastro.2017.88
22. Lee, SH, Yun, Y, Kim, SJ, Lee, EJ, Chang, Y, Ryu, S, et al. Association between cigarette smoking status and composition of gut microbiota: population-based cross-sectional study. J Clin Med. (2018) 7:282. doi: 10.3390/jcm7090282
23. Shanahan, ER, Shah, A, Koloski, N, Walker, MM, Talley, NJ, Morrison, M, et al. Influence of cigarette smoking on the human duodenal mucosa-associated microbiota. Microbiome. (2018) 6:150. doi: 10.1186/s40168-018-0531-3
24. Fricker, M, Goggins, BJ, Mateer, S, Jones, B, Kim, RY, Gellatly, SL, et al. Chronic cigarette smoke exposure induces systemic hypoxia that drives intestinal dysfunction. JCI Insight. (2018) 3:94040. doi: 10.1172/jci.insight.94040
25. Soleimani, F, Dobaradaran, S, De-la-Torre, GE, Schmidt, TC, and Saeedi, R. Content of toxic components of cigarette, cigarette smoke vs cigarette butts: a comprehensive systematic review. Sci Total Environ. (2022) 813:152667. doi: 10.1016/j.scitotenv.2021.152667
26. Gakidou, E, Afshin, A, Abajobir, AA, Abate, KH, Abbafati, C, Abbas, KM, et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet. (2017) 390:1345–422. doi: 10.1016/S0140-6736(17)32366-8
27. Mbulo, L, Palipudi, KM, Andes, L, Morton, J, Bashir, R, Fouad, H, et al. Secondhand smoke exposure at home among one billion children in 21 countries: findings from the global adult tobacco survey (GATS). Tob Control. (2016) 25:e95–e100. doi: 10.1136/tobaccocontrol-2015-052693
28. Su, Z, Xie, Y, Huang, Z, Cheng, A, Zhou, X, Wang, M, et al. Second hand smoke attributable disease burden in 204 countries and territories, 1990–2021: a systematic analysis from the global burden of disease study 2021. Respir Res. (2025) 26:174. doi: 10.1186/s12931-025-03228-3
29. Murray, CJL, Aravkin, AY, Zheng, P, Abbafati, C, Abbas, KM, Abbasi-Kangevari, M, et al. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet. (2020) 396:1223–49. doi: 10.1016/S0140-6736(20)30752-2
30. Satsangi, J, Silverberg, MS, Vermeire, S, and Colombel, JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. (2006) 55:749–53. doi: 10.1136/gut.2005.082909
31. Wells, GA, Shea, B, O’Connell, D, Peterson, J, Welch, V, Losos, M, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. London: BMJ. (2000).
32. DerSimonian, R, and Laird, N. Meta-analysis in clinical trials. Control Clin Trials. (1986) 7:177–88. doi: 10.1016/0197-2456(86)90046-2
33. Lindoso, L, Mondal, K, Venkateswaran, S, Somineni, HK, Ballengee, C, Walters, TD, et al. The effect of early-life environmental exposures on disease phenotype and clinical course of Crohn's disease in children. Am J Gastroenterol. (2018) 113:1524–9. doi: 10.1038/s41395-018-0239-9
34. Nowak, A, Pufal, E, Mierzwa, G, Kuczynska, R, Landowski, P, Kaminska, B, et al. Urine cotinine as a parameter of exposure to cigarette smoking in view of the clinical course of Crohn's disease in children and adolescents - own observation. Przeglad Gastroenterologiczny. (2008) 3:154.
35. Scharrer, S, Lissner, D, Primas, C, Reinisch, W, Novacek, G, Reinisch, S, et al. Passive smoking increases the risk for intestinal surgeries in patients with Crohn's disease. Inflamm Bowel Dis. (2021) 27:379–85. doi: 10.1093/ibd/izaa117
36. van der Heide, F, Dijkstra, A, Weersma, RK, Albersnagel, FA, van der Logt, EMJ, Faber, KN, et al. Effects of active and passive smoking on disease course of Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. (2009) 15:1199–207. doi: 10.1002/ibd.20884
37. Van Der Heide, F, Wassenaar, M, Van Der Linde, K, Spoelstra, P, Kleibeuker, JH, and Dijkstra, G. Effects of active and passive smoking on Crohn's disease and ulcerative colitis in a cohort from a regional hospital. Eur J Gastroenterol Hepatol. (2011) 23:255–61. doi: 10.1097/MEG.0b013e3283435233
38. van der Sloot, KWJ, Tiems, JL, Visschedijk, MC, Festen, EAM, van Dullemen, HM, Weersma, RK, et al. Cigarette smoke increases risk for colorectal neoplasia in inflammatory bowel disease. Clin Gastroenterol Hepatol. (2022) 20:798–805.e1. doi: 10.1016/j.cgh.2021.01.015
39. Mahendraratnam, N, Hutfless, S, Dudley-Brown, SL, Picco, MF, and Bayless, TM. Patterns of smoking and risk of hospitalization and steroid dependency in ulcerative colitis. Gastroenterology. (2009) 136:A355.
40. Abdallah, B, Arif, M, Al-Malki, M, Hourani, R, Al-Maadeed, T, Khodr, N, et al. The association between inflammatory bowel disease and exposure to tobacco smoking: a case-control study in Qatar. Int J Gen Med. (2023) 16:233–42. doi: 10.2147/IJGM.S393284
41. Aspberg, S, Dahlquist, G, Kahan, T, and Källén, B. Fetal and perinatal risk factors for inflammatory bowel disease. Acta Paediatr. (2006) 95:1001–4. doi: 10.1080/08035250600573151
42. Baron, S, Turck, D, Leplat, C, Merle, V, Gower-Rousseau, C, Marti, R, et al. Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Gut. (2005) 54:357–63. doi: 10.1136/gut.2004.054353
43. Basson, A, Swart, R, Jordaan, E, Mazinu, M, and Watermeyer, G. The association between childhood environmental exposures and the subsequent development of Crohn's disease in the Western Cape, South Africa. PLoS One. (2014) 9:e115492. doi: 10.1371/journal.pone.0115492
44. Bernstein, CN, Rawsthorne, P, Cheang, M, and Blanchard, JF. A population-based case control study of potential risk factors for IBD. Off J Am College Gastroenterol. (2006) 101:993-1002.
45. Blomster, TM, Koivurova, OP, Koskela, R, Herzig, KH, Talley, NJ, and Ronkainen, J. Pregnancy period and early-life risk factors for inflammatory bowel disease: a northern Finland birth cohort 1966 study. BMC Public Health. (2024) 24:1038. doi: 10.1186/s12889-024-18549-z
46. Hu, L, Wu, S, Shu, Y, Su, K, Wang, C, Wang, D, et al. Impact of maternal smoking, offspring smoking, and genetic susceptibility on Crohn’s disease and ulcerative colitis. J Crohn's Colitis. (2024) 18:671–8. doi: 10.1093/ecco-jcc/jjad200
47. Van Der Sloot, KWJ, Weersma, RK, Alizadeh, BZ, and Dijkstra, G. Identification of environmental risk factors associated with the development of inflammatory bowel disease. J Crohn's Colitis. (2020) 14:1662–71. doi: 10.1093/ecco-jcc/jjaa114
48. Amre, DK, Lambrette, P, Law, L, Krupoves, A, Chotard, V, Costea, F, et al. Investigating the hygiene hypothesis as a risk factor in pediatric onset Crohn's disease: a case-control study. Am J Gastroenterol. (2006) 101:1005–11. doi: 10.1111/j.1572-0241.2006.00526.x
49. Fantodji, C, Rousseau, M-C, Nicolau, B, Madathil, S, Benedetti, A, and Jantchou, P. Early life exposures and risk of inflammatory bowel disease: a nested case-control study in Quebec, Canada. Digest Liver Dis. (2025) 57:290–7. doi: 10.1016/j.dld.2024.09.011
50. Kondo, K, Ohfuji, S, Watanabe, K, Yamagami, H, Fukushima, W, Ito, K, et al. The association between environmental factors and the development of Crohn's disease with focusing on passive smoking: a multicenter case-control study in Japan. PLoS One. (2019) 14:e0216429. doi: 10.1371/journal.pone.0216429
51. Nishikawa, A, Tanaka, K, Miyake, Y, Nagata, C, Furukawa, S, Andoh, A, et al. Active and passive smoking and risk of ulcerative colitis: a case-control study in Japan. J Gastroenterol Hepatol. (2022) 37:653–9. doi: 10.1111/jgh.15745
52. Sigvardsson, I, Ludvigsson, J, Andersson, B, Stordal, K, and Marild, K. Tobacco smoke exposure in early childhood and later risk of inflammatory bowel disease: a Scandinavian birth cohort study. J Crohn's Colitis. (2024) 18:661–70. doi: 10.1093/ecco-jcc/jjae020
53. Eliakim, R, Reif, S, Lavy, A, Keter, D, Odes, S, Halak, A, et al. Passive smoking in patients with inflammatory bowel disease: an Israeli multicentre case-control study. Eur J Gastroenterol Hepatol. (2000) 12:975–9. doi: 10.1097/00042737-200012090-00002
54. Feeney, MA, Murphy, F, Clegg, AJ, Trebble, TM, Sharer, NM, and Snook, JA. A case–control study of childhood environmental risk factors for the development of inflammatory bowel disease. Eur J Gastroenterol Hepatol. (2002) 14:529–34. doi: 10.1097/00042737-200205000-00010
55. Gruber, M, Marshall, JR, Zielezny, M, and Lance, P. A case-control study to examine the influence of maternal perinatal behaviors on the incidence of Crohn's disease. Gastroenterol Nurs. (1996) 19:53–9. doi: 10.1097/00001610-199603000-00003
56. Lashner, BA, Shaheen, NJ, Hanauer, SB, and Kirschner, BS. Passive smoking is associated with an increased risk of developing inflammatory bowel disease in children. Am J Gastroenterol. (1993) 88:356. doi: 10.1111/j.1572-0241.1993.tb07545.x
57. Mahid, SS, Minor, KS, Stromberg, AJ, and Galandiuk, S. Active and passive smoking in childhood is related to the development of inflammatory bowel disease. Inflamm Bowel Dis. (2007) 13:431–8. doi: 10.1002/ibd.20070
58. Martins Junior, EV, Araujo, IS, Atallah, AN, and Miszputen, SJ. Smoking and inflammatory bowel disease: an epidemiological case-control study. Tabagismo e doenca inflamatoria intestinal: estudo epidemiologico caso-controle. (1996) 33:74–8.
59. Persson, PG, Ahlbom, A, and Hellers, G. Inflammatory bowel disease and tobacco smoke--a case-control study. Gut. (1990) 31:1377–81. doi: 10.1136/gut.31.12.1377
60. Russell, RK, Farhadi, R, Wilson, M, Drummond, H, Satsangi, J, and Wilson, DC. Perinatal passive smoke exposure may be more important than childhood exposure in the risk of developing childhood IBD. Gut. (2005) 54:1500–1; author reply 1.
61. Sandler, RS, Sandler, DP, McDonnell, CW, and Wurzelmann, JI. Childhood exposure to environmental tobacco smoke and the risk of ulcerative colitis. Am J Epidemiol. (1992) 135:603–8. doi: 10.1093/oxfordjournals.aje.a116339
62. Thompson, NP, Pounder, RE, and Wakefield, AJ. Perinatal and childhood risk factors for inflammatory bowel disease: a case-control study. Eur J Gastroenterol Hepatol. (1995) 7:385–90.
63. Uchiyama, K, Haruyama, Y, Shiraishi, H, Katahira, K, Abukawa, D, Ishige, T, et al. Association between passive smoking from the mother and pediatric Crohn's disease: a Japanese multicenter study. Int J Environ Res Public Health. (2020) 17:2926–2935. doi: 10.3390/ijerph17082926
64. Yu, Y, and Jin, Y. Examining the relationship between secondhand smoke and non-malignant digestive system diseases: Mendelian randomization evidence. Tob Induc Dis. (2025) 23:16.
65. Hodges, P, and Kelly, P. Inflammatory bowel disease in Africa: what is the current state of knowledge? Int Health. (2020) 12:222–30. doi: 10.1093/inthealth/ihaa005
66. Forbes, AJ, Frampton, CMA, Day, AS, Kaplan, GG, and Gearry, RB. The epidemiology of inflammatory bowel disease in Oceania: a systematic review and meta-analysis of incidence and prevalence. Inflamm Bowel Dis. (2024) 30:2076–86. doi: 10.1093/ibd/izad295
67. Jones, DT, Osterman, MT, Bewtra, M, and Lewis, JD. Passive smoking and inflammatory bowel disease: a meta-analysis. Am J Gastroenterol. (2008) 103:2382–93. doi: 10.1111/j.1572-0241.2008.01999.x
68. Allais, L, Kerckhof, F-M, Verschuere, S, Bracke, KR, De Smet, R, Laukens, D, et al. Chronic cigarette smoke exposure induces microbial and inflammatory shifts and mucin changes in the murine gut. Environ Microbiol. (2016) 18:1352–63. doi: 10.1111/1462-2920.12934
69. Biedermann, L, Brülisauer, K, Zeitz, J, Frei, P, Scharl, M, Vavricka, SR, et al. Smoking cessation alters intestinal microbiota: insights from quantitative investigations on human fecal samples using FISH. Inflamm Bowel Dis. (2014) 20:1496–501. doi: 10.1097/MIB.0000000000000129
70. Zuo, L, Li, Y, Wang, H, Wu, R, Zhu, W, Zhang, W, et al. Cigarette smoking is associated with intestinal barrier dysfunction in the small intestine but not in the large intestine of mice. J Crohn's Colitis. (2014) 8:1710–22. doi: 10.1016/j.crohns.2014.08.008
71. Ueno, A, Jijon, H, Traves, S, Chan, R, Ford, K, Beck, PL, et al. Opposing effects of smoking in ulcerative colitis and Crohn's disease may be explained by differential effects on dendritic cells. Inflamm Bowel Dis. (2014) 20:800–10. doi: 10.1097/MIB.0000000000000018
72. Sun, YP, Wang, HH, He, Q, and Cho, CH. Effect of passive cigarette smoking on colonic alpha7-nicotinic acetylcholine receptors in TNBS-induced colitis in rats. Digestion. (2007) 76:181–7. doi: 10.1159/000112643
73. Pu, W, Su, Z, Wazir, J, Zhao, C, Wei, L, Wang, R, et al. Protective effect of α7 nicotinic acetylcholine receptor activation on experimental colitis and its mechanism. Mol Med. (2022) 28:104. doi: 10.1186/s10020-022-00532-2
74. Hayashi, S, Hamada, T, Zaidi, SF, Oshiro, M, Lee, J, Yamamoto, T, et al. Nicotine suppresses acute colitis and colonic tumorigenesis associated with chronic colitis in mice. Am J. Physiol. Gastrointest. Liver Physiol. (2014) 307:G968–78. doi: 10.1152/ajpgi.00346.2013
75. Kanauchi, Y, Yamamoto, T, Yoshida, M, Zhang, Y, Lee, J, Hayashi, S, et al. Cholinergic anti-inflammatory pathway ameliorates murine experimental Th2-type colitis by suppressing the migration of plasmacytoid dendritic cells. Sci Rep. (2022) 12:54. doi: 10.1038/s41598-021-04154-2
76. Kawahara, R, Yasuda, M, Hashimura, H, Amagase, K, Kato, S, and Takeuchi, K. Activation of α7 nicotinic acetylcholine receptors ameliorates indomethacin-induced small intestinal ulceration in mice. Eur J Pharmacol. (2011) 650:411–7. doi: 10.1016/j.ejphar.2010.10.031
77. Kuenzig, ME, Lee, SM, Eksteen, B, Seow, CH, Barnabe, C, Panaccione, R, et al. Smoking influences the need for surgery in patients with the inflammatory bowel diseases: a systematic review and meta-analysis incorporating disease duration. BMC Gastroenterol. (2016) 16:143. doi: 10.1186/s12876-016-0555-8
78. To NFord, AC, and Gracie, DJ. Systematic review with meta-analysis: the effect of tobacco smoking on the natural history of ulcerative colitis. Aliment Pharmacol Ther. (2016) 44:117–26. doi: 10.1111/apt.13663
79. Verschuere, S, Bracke, KR, Demoor, T, Plantinga, M, Verbrugghe, P, Ferdinande, L, et al. Cigarette smoking alters epithelial apoptosis and immune composition in murine GALT. Lab Investig. (2011) 91:1056–67. doi: 10.1038/labinvest.2011.74
80. Berkowitz, L, Schultz, BM, Salazar, GA, Pardo-Roa, C, Sebastián, VP, Álvarez-Lobos, MM, et al. Impact of cigarette smoking on the gastrointestinal tract inflammation: opposing effects in Crohn’s disease and ulcerative colitis. Front Immunol. (2018) 9:74. doi: 10.3389/fimmu.2018.00074
81. Lakhan, SE, and Kirchgessner, A. Anti-inflammatory effects of nicotine in obesity and ulcerative colitis. J Transl Med. (2011) 9:129. doi: 10.1186/1479-5876-9-129
82. Chen, X, Jansen, L, Guo, F, Hoffmeister, M, Chang-Claude, J, and Brenner, H. Smoking, genetic predisposition, and colorectal cancer risk. Clin Transl Gastroenterol. (2021) 12:e00317. doi: 10.14309/ctg.0000000000000317
83. Martínez, C, Martínez-Sánchez, JM, Robinson, G, Bethke, C, and Fernández, E. Protection from secondhand smoke in countries belonging to the WHO European region: an assessment of legislation. Tob Control. (2014) 23:403–11. doi: 10.1136/tobaccocontrol-2012-050715
84. Schiavone, S, Anderson, C, Mons, U, and Winkler, V. Prevalence of second-hand tobacco smoke in relation to smoke-free legislation in the European Union. Prev Med. (2022) 154:106868. doi: 10.1016/j.ypmed.2021.106868
85. Joossens, L, and Raw, M. The tobacco control scale: a new scale to measure country activity. Tob Control. (2006) 15:247–53. doi: 10.1136/tc.2005.015347
86. Casetta, B, Videla, AJ, Bardach, A, Morello, P, Soto, N, Lee, K, et al. Association between cigarette smoking prevalence and income level: a systematic review and meta-analysis. Nicotine Tob Res. (2017) 19:1401–7. doi: 10.1093/ntr/ntw266
Keywords: inflammatory bowel disease, ulcerative colitis, passive smoking, smoking, tobacco, pregnancy, Crohn’s disease, second hand smoke
Citation: Mahajan A, Gupta B, Peterson A, Iyngkaran G and Valaydon Z (2025) Passive smoking exposure and incidence and disease outcomes of inflammatory bowel disease: a systematic review and meta-analysis. Front. Public Health. 13:1670320. doi: 10.3389/fpubh.2025.1670320
Edited by:
Duolong Zhu, Baylor College of Medicine, United StatesReviewed by:
Siliang Li, Rice University, United StatesYupeng Fan, University of Oklahoma, United States
Copyright © 2025 Mahajan, Gupta, Peterson, Iyngkaran and Valaydon. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Akanksha Mahajan, YWthbmtzaGEubWFoYWphbjJAbW9uYXNoaGVhbHRoLm9yZw==